Cassava Sciences, Inc.
SAVACassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Simufilam
Alzheimer Disease
Simufilam 100 mg oral tablet
Alzheimer Disease
Simufilam 100 mg tablet
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Simufilam | Phase 3 | Alzheimer Disease | - | - |
Simufilam 100 mg oral tablet | Phase 2 | Alzheimer Disease | - | - |
Simufilam 100 mg tablet | Phase 2 | Alzheimer Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)